NCT02657005 - TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 31, 2022

Study Completion Date

June 30, 2022

Conditions

Sarcoma, Ewing

Interventions

DRUG

TK216

Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein

Trial Locations (9)

Memorial Sloan Kettering Cancer Center, New York

Children's National Hospital, Washington D.C.

Duke Cancer Institute, Durham

Cleveland Clinic Foundation, Cleveland

Texas Children's Cancer & Hematology Centers, Baylor College, Houston

UT MD Anderson Cancer Center, Houston

Children's Hospital of Colorado, Aurora

UCLA Jonsson Comprehensive Cancer Center, Los Angeles

Oregon Health & Science University, Portland